Quintiles Launches Continuous Glucose Monitoring Services to Enhance Diabetes Outcomes

Quintiles Transnational Holdings Inc

revealed Friday the launch of its fresh Continuous Glucose Monitoring (CGM) service offering. According to the company, this fresh solution integrates innovative, wearable technology with Quintiles' deep therapeutic and analytical expertise to help enhance the efficiency and quality of diabetes-focused clinical trials. Quintiles said that the new CGM offering would provide investigators with access to a myriad of customized data analytics besides performance reports through its award-winning Quintiles Infosario technology platform. The company was confident that these optimized glycemic data sets could be analyzed more efficiently to uncover trends like non-compliance and potential safety triggers quicker than traditional diabetes monitoring models. In addition, Quintiles experts from its Diabetes Center of Excellence would offer dedicated support for the offering – combining data and therapeutic expertise to drive smarter protocol design and enhance patient safety and compliance. The company's President for Data Services, Safety and Regulator Services, Margaret Keegan, commented, "According to the International Diabetes Federation (IDF), every six seconds, a person dies from diabetes-related causes and almost half of those deaths are people under the age of 60." He continued to say, "With diabetes diagnoses on the rise, the need for innovative and accessible treatments also increases. CGM can provide a variety of in-depth measures from diabetes patients – information that can be used to enhance the way patients are treated for diabetes and why this new offering is so critical." The company disclosed that through the offering, continuous glucose measurements would be captured by a wearable sensor and wirelessly sent to a receiver, recording readings throughout the day. Shares of the company traded 1.72 percent higher on Thursday.